SUNITINIB SUN sunitinib (as malate) 12.5 mg capsule bottle

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

sunitinib malate, Quantity: 16.706 mg (Equivalent: sunitinib, Qty 12.5 mg)

Disponibbli minn:

Sun Pharma ANZ Pty Ltd

Għamla farmaċewtika:

Capsule, hard

Kompożizzjoni:

Excipient Ingredients: Gelatin; mannitol; magnesium stearate; iron oxide red; titanium dioxide; purified water; croscarmellose sodium; povidone; propylene glycol; butan-1-ol; isopropyl alcohol; Shellac; ethanol absolute; ammonia; potassium hydroxide

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

28 capsules

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

SUNITINIB SUN is indicated for:,? treatment of advanced renal cell carcinoma (RCC),? treatment of gastrointestinal stromal tumour (GIST) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic NET).

Sommarju tal-prodott:

Visual Identification: Hard gelatin Size 4 capsule with opaque reddish brown cap and opaque reddish brown body, self-lock capsule, imprinted with white ink RM53 on the cap & body; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2021-02-22